AI In Drug Repurposing Market Size Worth USD 6.29 Billion by 2034 | CAGR: 20.1%

The AI in drug repurposing market market size is expected to reach USD  6.29 Billion by 2034, according to a new study by Polaris Market Research. The report “AI In Drug Repurposing Market Size, Share, Trends, Industry Analysis Report By Drug Type, By Therapeutic Area, By Deployment Mode, By End User, By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The AI in Drug Repurposing market is experiencing robust growth, driven by rising global demand for cost-effective and accelerated drug development, increasing prevalence of chronic and rare diseases, and the need to identify new therapeutic uses for existing drugs efficiently.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/ai-in-drug-repurposing-market/request-for-sample

Market growth is supported by advances in machine learning, deep learning, and AI-driven predictive analytics. The increasing availability of large-scale clinical and multi-omics datasets is further driving adoption. Leading players are developing innovative and scalable AI platforms that improve drug discovery efficiency, lower development costs, and enable personalized therapies while addressing unmet medical needs.

AI In Drug Repurposing Market Report Highlights

• Based on drug type, the small molecules segment dominated the market in 2024, driven by well-established approval pathways, cost-effectiveness, and extensive data availability from previous clinical trials that support AI-enabled repurposing.
• By therapeutic area, the oncology segment held the largest share in 2024, supported by a high volume of cancer-related research and the growing adoption of AI-driven models for precision drug repositioning.
• Based on deployment mode, the cloud-based segment led the market in 2024, owing to its scalability, flexibility, and ability to efficiently process large biomedical and clinical datasets.
• By end-user, the pharmaceutical and biotechnology segment accounted for the largest share in 2024, fueled by widespread adoption of AI-driven platforms to accelerate discovery-to-market timelines and optimize R&D expenditure.
• North America dominated the market in 2024, supported by expanding collaborations between AI startups and leading research institutions to identify and validate repurposed drug candidates.
• Asia Pacific experienced steady growth in 2024, driven by increasing partnerships between global pharmaceutical firms and regional AI startups, enabling faster identification of viable repurposing opportunities.
• A few key global players include Atomwise, Inc., BenevolentAI Limited, BioAge Labs, Inc., BioXcel Therapeutics, Inc., BostonGene Corporation, Cyclica Inc., Exscientia plc, Ginkgo Bioworks Holdings, Inc., Healx Ltd., Ignota Labs Ltd., Insilico Medicine, Inc., Melior Discovery, Inc., Recursion Pharmaceuticals, Inc., TxGNN, Inc., and United Therapeutics Corporation.

Polaris Market Research has segmented the market report on the basis of drug type, therapeutic area, deployment mode, end user, and region:

By Drug Type Outlook (Revenue, USD Billion, 2020–2034)

• Small Molecules
• Biologics
• Vaccines
• Peptides
• Others

By Therapeutic Area Outlook (Revenue, USD Billion, 2020–2034)

• Oncology
• Neurology
• Cardiovascular Diseases
• Infectious Diseases
• Immunology
• Metabolic Disorders
• Rare Diseases
• Others

By Deployment Mode Outlook (Revenue, USD Billion, 2020–2034)

• Cloud-based
• On-premises

By End User Outlook (Revenue, USD Billion, 2020–2034)

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Healthcare Providers
• Others

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America

• US
• Canada

• Europe

• Germany
• France
• UK
• Italy
• Spain
• Netherlands
• Russia
• Rest of Europe

• Asia Pacific

• China
• Japan
• India
• Malaysia
• South Korea
• Indonesia
• Australia
• Vietnam
• Rest of Asia Pacific

• Middle East & Africa

• Saudi Arabia
• UAE
• Israel
• South Africa
• Rest of Middle East & Africa

• Latin America

• Mexico
• Brazil
• Argentina
• Rest of Latin America